Business
Optimi Health Completes Largest-to-Date MDMA Export to Australia for PTSD Therapy
1,000 GMP doses of MDMA now reaching patients with PTSD under Australia's Authorised Prescriber Scheme; Department of Veterans' Affairs to fund treatment for veterans Vancouver, British Columbia--(Newsfile Corp. - May 8, 2025) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a Canadian drug manufacturer and formulator of GMP-grade MDMA and natural psilocybin, has completed its largest international export to date of MDMA capsules to Australia, supporting t
About this update from Optimi Health Corp.
[{"type":"text","content":"1,000 GMP doses of MDMA now reaching patients with PTSD under Australia's Authorised Prescriber Scheme; Department of Veterans' Affairs to fund treatment for veterans","length":174,"tagName":"p","attribs":{"class":"nfSubHeading"},"className":""},{"type":"text","content":"Vancouver, British Columbia--(Newsfile Corp. - May 8, 2025) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a Canadian drug manufacturer and formulator of GMP-grade MDMA and natural psilocybin, has completed its largest international export to date of MDMA capsules to Australia, supporting the treatment of Post-Traumatic Stress Disorder (PTSD) under the country's Authorised Prescriber Scheme.","length":465,"tagName":"p"},{"type":"text","content":"The shipment, conducted in partnership with Mind Medicine Australia, included 1,000 GMP MDMA capsules in both 40mg and 60mg strengths. Import approval was granted by Australia's Therapeutic Goods Administration (TGA), with matching export permits issued from Health Canada. The capsules were manufactured and shipped under Optimi's Drug Establishment Licence (DEL), authorizing global distribution for PTSD treatment through licensed pharmacy networks and authorised clinics across Australia.","length":500,"tagName":"p"},{"type":"text","content":"In a major step forward for access, the Australian Department of Veterans' Affairs (DVA) recently announced that it will fund MDMA-assisted therapy for veterans diagnosed with PTSD. This marks the first time a federal agency in Australia has committed to reimbursing psychedelic-assisted treatment, reinforcing national momentum toward broader mental health care solutions and highlighting the need for safe, GMP-supplied medicines.","length":436,"tagName":"p"},{"type":"text","content":"Source: https://www.theaustralian.com.au/health/mental-health/dva-to-fund-psychedelic-medicine-for-veterans-with-ptsd-depression/news-story/4a56bca1577561bf22fe6368f3d2fb91","length":172,"tagName":"p"},{"type":"text","content":"Mind Medicine Australia welcomed the announcement as a meaningful step toward broadening access to care for those who need it most.","length":131,"tagName":"p"},{"type":"text","content":""The announcement from the Department of Veterans' Affairs to fund MDMA-assisted therapy is a maj...